714568-86-2

Upstream product

• 6384-18-5 dimethyl D-aspartate 
• 1493-27-2 ortho-nitrofluorobenzene 
• 2177-62-0 β-methyl L-aspartate 

Downstream Products

• 565460-55-1 methyl {(2R)-3-oxo-1,2,3,4-tetrahydroquinoxalin-2-yl}acetate 
• 565460-58-4 N-[2-(4-cyanophenyl)ethyl]-2-{(2R)-1-[(3,4-dichlorophenyl)sulfonyl]-3-oxo-1,2,3,4-tetrahydroquinoxalin-2-yl}acetamide 
• 565460-56-2 methyl {(2R)-1-[(3,4-dichlorophenyl)sulfonyl]-3-oxo-1,2,3,4-tetrahydroquinoxalin-2-yl}acetate 
• 565460-57-3 {(2R)-1-[(3,4-dichlorophenyl)sulfonyl]-3-oxo-1,2,3,4-tetrahydroquinoxalin-2-yl}acetic acid 
• 714569-31-0 2-{(2R)-1-[(3,4-dichlorophenyl)sulfonyl]-3-oxo-1,2,3,4-tetrahydroquinoxalin-2-yl}ethyl methanesulfonate 
• 714569-35-4 S-(2-{(2R)-1-[(3,4-dichlorophenyl)sulfonyl]-3-oxo-1,2,3,4-tetrahydroquinoxalin-2-yl}ethyl) ethanethioate 
• 714570-20-4 {(2R)-1-[(3,4-dichlorophenyl)sulfonyl]-4-methyl-3-oxo-1,2,3,4-tetrahydroquinoxalin-2-yl}acetic acid 
• 714569-77-4 [(2R)-1-(3,4-difluorobenzoyl)-3-oxo-1,2,3,4-tetrahydroquinoxalin-2-yl]-acetic acid 
• 1056950-86-7 (3R)-3-(2-aminoethyl)-4-[(3,4-dichloro-phenyl)sulfonyl]-3,4-dihydroquinoxalin-2(1H)-one 
• 714569-27-4 (3R)-4-[(3,4-dichlorophenyl)sulfonyl]-3-(2-hydroxyethyl)-3,4-dihydroquinoxalin-2(1H)-one 
• 714569-87-6 [(2R)-1-benzyl-3-oxo-1,2,3,4-tetrahydroquinoxalin-2-yl]acetic acid 

Relevant academic research and scientific papers

Iron- or Zinc-Mediated Synthetic Approach to Enantiopure Dihydroquinoxalinones

A general and efficient synthesis of enantiopure dihydroquinoxalinones has been developed using naturally occurring amino acids as starting materials. The reductive cyclization of N-(o-nitroaryl)amino esters was performed by using iron and zinc metal under mild conditions in a water/ethyl acetate mixture. The corresponding dihydroquinoxalinones were obtained in moderate to high yields and high enantiomeric purity, among which 7 new compounds were unprecedented in the literature.

2-QUINOXALINONE DERIVATIVES AS BRADYKININ ANTAGONISTS AND NOVEL COMPOUNDS

2-Quinoxalinone derivatives are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.